Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 7/20 | 0.68 |
| ▸ | DRD3 | P35462 | 3/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.64 |
| ▸ | DRD2 | P14416 | 3/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | DRD1 | P21728 | 2/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | HTR6 | P50406 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6801909 | 0.98 | SETD7 (0.66) | SETD7DRD3HTR1ADRD2CHRM2 | |
| SCHEMBL6803898 | 0.91 | SETD7 (0.71) | SETD7DRD3HTR1ADRD2CHRM2 | |
| SCHEMBL9455504 | 0.84 | SETD7 (0.68) | SETD7DRD3HTR1ADRD2CHRM2 | |
| Hydrochloric Acid SCHEMBL7212508 | 0.83 | SETD7 (0.77) | SETD7DRD3HTR1ADRD2CHRM2 | |
| SCHEMBL6808721 | 0.83 | SETD7 (0.65) | SETD7DRD3HTR1ADRD2CHRM2 | |
| SCHEMBL9034546 | 0.82 | SETD7 (0.64) | SETD7DRD3HTR1ADRD2CHRM2 | |
| SCHEMBL7218739 | 0.82 | SETD7 (0.75) | SETD7DRD3HTR1ADRD2CHRM2 | |
| Hydrochloric Acid SCHEMBL7212638 | 0.81 | SETD7 (0.62) | SETD7DRD3HTR1ADRD2CHRM2 | |
| SCHEMBL10408872 | 0.81 | SETD7 (0.62) | SETD7DRD3HTR1ADRD2CHRM2 | |
| SCHEMBL10409953 | 0.81 | SETD7 (0.67) | SETD7DRD3HTR1ADRD2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278329-B2 | Antagonizing N-type calcium channels; use as analgesic, neurodegenerative diseases, brain injury, bronchial asthma, unstable angina and irritable colitis, drug withdrawal symptoms; t-butyl 2-[4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-piperidinyl]-2-oxoethylcarbamate for example | AJINOMOTO CO., INC. (JP) | 2012-10-02 | — | — | US | disclosed |
| US-7713957-B2 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7462630-B2 | Diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2004-08-26 | — | — | US | disclosed |
| EP-0976735-B1 | PROCESS FOR PRODUCING PIPERIDINECARBOXYLIC ACID AMIDES | AJINOMOTO KK (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1325913-A2 | Piperidinecarboxylic acid amide derivatives | Ajinomoto Co., Inc. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-6355804-B1 | REACTING 2-OXAZOLINE COMPOUND WITH PIPERIDINE DERIVATIVE OR SALT THEREOF, IN PRESENCE OF ACID | AJINOMOTO CO., INC. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6207834-B1 | REACTING 2-OXAZOLINE COMPOUND WITH A PIPERIDINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0976735-A1 | PROCESS FOR PRODUCING PIPERIDINECARBOXYLIC ACID AMIDES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-4929621-A | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | SYNTHELABO (FR) | 1990-05-29 | — | — | US | disclosed |
| US-4891376-A | MIGRAINE | SYNTHELABO (FR) | 1990-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | CACNA1B, CACNA1G, CACNA1C | SETD7 4652/4885DRD3 941/4885HTR1A 1771/4885 |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | CACNA1E, CACNA1H, CACNA1D | SETD7 3137/4885DRD3 499/4885HTR1A 431/4885 |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | CACNA1E, CACNA1D, CACNA1H | SETD7 2986/4885DRD3 305/4885HTR1A 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.